DSC_6739
Saturday, February 21, 2026
18.4
C
Bengaluru
Hot topics
Coughing All the Way to the Bank: The High Cost of India’s Booming Cough Syrup Market
India’s cough syrup market, worth over ₹21,800 crore in...
Digital Darwinism or Digital Expert – The Choice for Indian Pharma is Clear
It is heartening to see that Pharma marketers have...
Can Servier Hit the INR 1000 Cr Mark with Drugs + Diagnostics GTM?
In an industry often defined by blockbuster-driven strategies and...
Novo Nordisk’s Big Reset: What 9,000 Job Cuts Signal for Pharma’s Future
For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged.
But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.
Opportunities for Indian Pharma
Articles by Bhaskar Chakravorty, Hanno Wolfram, K. Hariram, Krishna Singh, Shreenivas S, Chandan Kumar and Salil Kallianpur
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Hot topics
Incentives in Healthcare: The Quiet Force Shaping Outcomes
In 2017, economist Richard Thaler won the Nobel Prize...
Navigating India’s Diverging Health Landscape and Field Force Optimisation
India’s health map is splitting into two distinct opportunity...
Are Digital Pharmacies a Game Changer?
Lower prices, discounts, convenience of ordering and home delivery are some of the benefits for consumers with e-pharmacies. The anonymity of the internet encourages patients to seek information about medicines that they would otherwise avoid. Mental health is one area where the consumers wish to maintain confidentiality and opt for online consultation and medication.
IMS Health Market Reflection Report for August 2016
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,426 crores in the month of August 2016 clocking a strong 18% growth over same period last year (SPLY). This was the second consecutive month where the IPM crossed the 10,000 crore mark.
Indian Pharma – The Emerging Role of Hybrid Sales Model
COVID-19 has accelerated the shift in how pharma was engaging with HCPs, professional organisations and even patients in India from a sales to more of a scientific, unbiased and balanced marketing communications. As one of the business leader from a prominent MNC said, “For the first time we are seeing a certain shift in HCP’s preference for scientific communication for innovators companies. MSLs and scientific operation teams will be playing a key role in the near future.”
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Executive Summary — The Paradox of Scale
In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
Newsletter
Get important news delivered directly to your inbox and stay connected!